| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Kinase Fusion Gene:CDK16_USP9X |
Kinase Fusion Protein Summary |
 Kinase Fusion gene summary |
| Kinase Fusion partner gene information | Kinase Fusion gene name: CDK16_USP9X | KinaseFusionDB ID: KFG1119 | FusionGDB2.0 ID: KFG1119 | Hgene | Tgene | Gene symbol | CDK16 | USP9X | Gene ID | 5127 | 8239 | |
| Gene name | cyclin dependent kinase 16 | ubiquitin specific peptidase 9 X-linked | ||||||||||
| Synonyms | PCTAIRE|PCTAIRE1|PCTGAIRE|PCTK1 | DFFRX|FAF|FAF-X|FAM|MRX99|MRXS99F|XLID99|hFAM | ||||||||||
| Cytomap | Xp11.3 | Xp11.4 | ||||||||||
| Type of gene | protein-coding | protein-coding | ||||||||||
| Description | cyclin-dependent kinase 16PCTAIRE-motif protein kinase 1cell division protein kinase 16serine/threonine-protein kinase PCTAIRE-1testis secretory sperm-binding protein Li 224n | probable ubiquitin carboxyl-terminal hydrolase FAF-XDrosophila fat facets related, X-linkeddeubiquitinating enzyme FAF-Xfat facets in mammalsfat facets protein related, X-linkedfat facets-like, X-linkedubiquitin specific protease 9, X chromosome (fa | ||||||||||
| Modification date | 20240403 | 20240411 | ||||||||||
| UniProtAcc | Q00536 | Q93008 | ||||||||||
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000276052, ENST00000357227, ENST00000457458, ENST00000517997, ENST00000518022, | ENST00000324545, ENST00000378308, | |||||||||
| Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: CDK16 [Title/Abstract] AND USP9X [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | CDK16(47080370)-USP9X(40977867), # samples:1 | |||||||||||
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | CDK16 | GO:0010508 | positive regulation of autophagy | 32098961 |
| Tgene | USP9X | GO:0006307 | DNA alkylation repair | 25944111 |
| Tgene | USP9X | GO:0016562 | protein import into peroxisome matrix, receptor recycling | 22371489 |
| Tgene | USP9X | GO:0016579 | protein deubiquitination | 19135894 |
| Tgene | USP9X | GO:0030509 | BMP signaling pathway | 19135894 |
| Tgene | USP9X | GO:0035520 | monoubiquitinated protein deubiquitination | 22371489 |
| Tgene | USP9X | GO:0060271 | cilium assembly | 25552655 |
| Tgene | USP9X | GO:0061824 | cytosolic ciliogenesis | 28498859 |
| Tgene | USP9X | GO:0070536 | protein K63-linked deubiquitination | 33378666 |
| Tgene | USP9X | GO:1904515 | positive regulation of TORC2 signaling | 33378666 |
| Kinase Fusion gene breakpoints across CDK16 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Kinase Fusion gene breakpoints across USP9X (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
| Kinase Fusion gene information. |
| Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
| ChiTaRS5.0 | BI019783 | CDK16 | chrX | 47080370 | USP9X | chrX | 40977867 |
Top |
Kinase Fusion ORF Analysis |
| Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:47080370/:40977867) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| CDK16 | USP9X |
| FUNCTION: Protein kinase that plays a role in vesicle-mediated transport processes and exocytosis. Regulates GH1 release by brain neurons. Phosphorylates NSF, and thereby regulates NSF oligomerization. Required for normal spermatogenesis. Regulates neuron differentiation and dendrite development (By similarity). Plays a role in the regulation of insulin secretion in response to changes in blood glucose levels. Can phosphorylate CCNY at 'Ser-336' (in vitro). {ECO:0000250, ECO:0000269|PubMed:22184064, ECO:0000269|PubMed:22796189, ECO:0000269|PubMed:22798068}. | FUNCTION: Deubiquitinase involved both in the processing of ubiquitin precursors and of ubiquitinated proteins (PubMed:19135894, PubMed:25944111, PubMed:18254724, PubMed:22371489, PubMed:29626158). May therefore play an important regulatory role at the level of protein turnover by preventing degradation of proteins through the removal of conjugated ubiquitin (PubMed:19135894, PubMed:25944111, PubMed:22371489, PubMed:18254724, PubMed:29626158). Specifically hydrolyzes 'Lys-63'-, 'Lys-48'-, 'Lys-29'- and 'Lys-33'-linked polyubiquitins chains (PubMed:25944111, PubMed:18254724, PubMed:33378666). Essential component of TGF-beta/BMP signaling cascade (PubMed:19135894). Specifically deubiquitinates monoubiquitinated SMAD4, opposing the activity of E3 ubiquitin-protein ligase TRIM33 (PubMed:19135894). Deubiquitinates alkylation repair enzyme ALKBH3 (PubMed:25944111). OTUD4 recruits USP7 and USP9X to stabilize ALKBH3, thereby promoting the repair of alkylated DNA lesions (PubMed:25944111). Deubiquitinates mTORC2 complex component RICTOR at 'Lys-294' by removing 'Lys-63'-linked polyubiquitin chains, stabilizing RICTOR and enhancing its binding to MTOR, thus promoting mTORC2 complex assembly (PubMed:33378666). Regulates chromosome alignment and segregation in mitosis by regulating the localization of BIRC5/survivin to mitotic centromeres (PubMed:16322459). Involved in axonal growth and neuronal cell migration (PubMed:24607389). Regulates cellular clock function by enhancing the protein stability and transcriptional activity of the core circadian protein BMAL1 via its deubiquitinating activity (PubMed:29626158). Acts as a regulator of peroxisome import by mediating deubiquitination of PEX5: specifically deubiquitinates PEX5 monoubiquitinated at 'Cys-11' following its retrotranslocation into the cytosol, resetting PEX5 for a subsequent import cycle (PubMed:22371489). Deubiquitinates PEG10 (By similarity). {ECO:0000250|UniProtKB:P70398, ECO:0000269|PubMed:16322459, ECO:0000269|PubMed:18254724, ECO:0000269|PubMed:19135894, ECO:0000269|PubMed:22371489, ECO:0000269|PubMed:24607389, ECO:0000269|PubMed:25944111, ECO:0000269|PubMed:29626158, ECO:0000269|PubMed:33378666}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| - Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of CDK16_USP9X |
| Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
| Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
| CDK16 | Q00536 | human | PRKAR1A | P10644 | S83 | DsREDEIsPPPPNPV | |
| CDK16 | Q00536 | human | PRC1 | O43663 | T481 | RrGLAPNtPGkARkL | |
| CDK16 | Q00536 | human | CDKN1B | P46527 | S10 | NVRVSNGsPsLErMD | |
| CDK16 | Q00536 | human | CCNY | Q8ND76 | S336 | NLtLPRWsPAIIS__ |
| Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
| Enriched GO biological processes of the phosphorylation target genes of the kinase |
| Kinase | GOID | GO term | P.adjust |
| CDK16 | ID | Description | 0.00e+00 |
| CDK16 | GO:0071900 | regulation of protein serine/threonine kinase activity | 3.40e-03 |
| CDK16 | GO:0000079 | regulation of cyclin-dependent protein serine/threonine kinase activity | 1.00e-02 |
| CDK16 | GO:1904029 | regulation of cyclin-dependent protein kinase activity | 1.00e-02 |
| CDK16 | GO:0071901 | negative regulation of protein serine/threonine kinase activity | 1.04e-02 |
| CDK16 | GO:0006469 | negative regulation of protein kinase activity | 2.59e-02 |
| CDK16 | GO:0033673 | negative regulation of kinase activity | 2.59e-02 |
| CDK16 | GO:0051348 | negative regulation of transferase activity | 2.67e-02 |
| CDK16 | GO:0033002 | muscle cell proliferation | 2.67e-02 |
| CDK16 | GO:0140014 | mitotic nuclear division | 2.67e-02 |
| CDK16 | GO:0001933 | negative regulation of protein phosphorylation | 2.67e-02 |
| CDK16 | GO:0042326 | negative regulation of phosphorylation | 2.67e-02 |
| CDK16 | GO:0060768 | regulation of epithelial cell proliferation involved in prostate gland development | 2.67e-02 |
| CDK16 | GO:0045936 | negative regulation of phosphate metabolic process | 2.67e-02 |
| CDK16 | GO:0010563 | negative regulation of phosphorus metabolic process | 2.67e-02 |
| CDK16 | GO:0051256 | mitotic spindle midzone assembly | 2.67e-02 |
| CDK16 | GO:0060767 | epithelial cell proliferation involved in prostate gland development | 2.67e-02 |
| CDK16 | GO:0000022 | mitotic spindle elongation | 2.67e-02 |
| CDK16 | GO:0071236 | cellular response to antibiotic | 2.67e-02 |
| CDK16 | GO:0071377 | cellular response to glucagon stimulus | 2.67e-02 |
| CDK16 | GO:0140694 | non-membrane-bounded organelle assembly | 2.67e-02 |
| CDK16 | GO:0071285 | cellular response to lithium ion | 2.67e-02 |
| CDK16 | GO:0051231 | spindle elongation | 2.67e-02 |
| CDK16 | GO:0051255 | spindle midzone assembly | 2.67e-02 |
| CDK16 | GO:0043434 | response to peptide hormone | 2.67e-02 |
| CDK16 | GO:0031400 | negative regulation of protein modification process | 2.67e-02 |
| CDK16 | GO:0000280 | nuclear division | 2.67e-02 |
| CDK16 | GO:0010226 | response to lithium ion | 2.67e-02 |
| CDK16 | GO:0045737 | positive regulation of cyclin-dependent protein serine/threonine kinase activity | 2.67e-02 |
| CDK16 | GO:0046007 | negative regulation of activated T cell proliferation | 2.67e-02 |
| CDK16 | GO:2000479 | regulation of cAMP-dependent protein kinase activity | 2.67e-02 |
| CDK16 | GO:0044772 | mitotic cell cycle phase transition | 2.71e-02 |
| CDK16 | GO:0043086 | negative regulation of catalytic activity | 2.71e-02 |
| CDK16 | GO:0006977 | DNA damage respons | 3.81e-03 |
| CDK16 | GO:1904031 | positive regulation of cyclin-dependent protein kinase activity | 2.71e-02 |
| CDK16 | GO:0048285 | organelle fission | 2.71e-02 |
| CDK16 | GO:0033762 | response to glucagon | 3.17e-02 |
| CDK16 | GO:0045736 | negative regulation of cyclin-dependent protein serine/threonine kinase activity | 3.28e-02 |
| CDK16 | GO:1904030 | negative regulation of cyclin-dependent protein kinase activity | 3.28e-02 |
| CDK16 | GO:0031571 | mitotic G1 DNA damage checkpoint signaling | 3.77e-02 |
| CDK16 | GO:0044819 | mitotic G1/S transition checkpoint signaling | 3.77e-02 |
| CDK16 | GO:0010458 | exit from mitosis | 3.97e-02 |
| CDK16 | GO:0031116 | positive regulation of microtubule polymerization | 3.97e-02 |
| CDK16 | GO:0031112 | positive regulation of microtubule polymerization or depolymerization | 4.28e-02 |
| CDK16 | GO:0046677 | response to antibiotic | 4.28e-02 |
| CDK16 | GO:0070306 | lens fiber cell differentiation | 4.28e-02 |
| CDK16 | GO:1904706 | negative regulation of vascular associated smooth muscle cell proliferation | 4.76e-02 |
| CDK16 | GO:0046006 | regulation of activated T cell proliferation | 4.88e-02 |
| CDK16 | GO:0045214 | sarcomere organization | 4.89e-02 |
| CDK16 | GO:0050798 | activated T cell proliferation | 5.00e-02 |
Top |
Related Drugs to CDK16_USP9X |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
| Distribution of the number of studies mentioning CDK16-USP9X and kinase inhibitors the PubMed Abstract (04-01-2024) |
| Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to CDK16_USP9X |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
| MeSH ID | MeSH term |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
| Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
| Clinical Trials from clinicaltrials.gov (06-17-2024) |
| Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |
Copyright 2024-Present -The University of Texas Health Science Center at Houston
Web File Viewing | Emergency Information |Campus Carry|Site Policies |